August 27, 2026 | Intelligent Commercialization, Pharma, healthcare
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

In our latest series of articles, our experts explore how Intelligent Commercialization™ is helping pharma teams turn insights into action across the lifecycle.
This content was provided by Inizio
Latest Content from Inizio
Published in eyeforpharma June 2017 by Marc Yates
Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase…
Watch our short video to see how we have grown. Please note the video comes with some fun, themed music. https://www.researchpartnership.com/news/2017/06/research-partnership-is-celebrating-20-years-in-bus…
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in…
Research Partnership is delighted to welcome Anne Cunningham and Morten Andersen and announce that Sue Rees has joined our specialist Emerging Markets team.
We are delighted to be presenting a paper and exhibiting at the Pharmaceutical Market Research Conference 13-14 June in Bay Area close to our new office in San Francisco.Representing Research…
Visit us on stand number 14
We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been…
Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase…
